Abstract:Background and purpose: The production of metallo-ss-lactamases is a major mechanisms adopted by bacterial pathogens to resist carbapenems. Repurposing approved drugs to restore the efficacy of carbapenems represents an efficient and costeffective approach to fight infections caused by carbapenem resistant pathogens. Experimental approach: The nitrocefin hydrolysis assay was employed to screen potential New Delhi metallo-lactamase-1 (NDM-1) inhibitors from a commercially available U.S. Food and Drug Administration (FDA) approved drug library. The mechanism of inhibition was clarified by metal restoration, inductively coupled plasma mass spectrometry (ICP-MS) and molecular dynamics simulation. The in vitro synergistic antibacterial effect of the identified inhibitors with meropenem was determined by the checkerboard minimum inhibitory concentration (MIC) assay, time-dependent killing assay and combined disc test. Three mouse infection models were used to further evaluate the in vivo therapeutic efficacy of combined therapy. Key results: Twelve FDA-approved compounds were initially screened to inhibit the ability of NDM-1 to hydrolyse nitrocefin. Among these compounds, dexrazoxane, embelin, candesartan cilexetil and nordihydroguaiaretic acid were demonstrated to inhibit all tested metallo-ss-lactamases and showed an in vitro synergistic bactericidal effect with meropenem against metallo-ss-lactamases-producing bacteria. Dexrazoxane, embelin and candesartan cilexetil are metal ion chelating agents, while the inhibition of NDM-1 by nordihydroguaiaretic acid involves its direct binding to the active region of NDM-1. Furthermore, these four drugs dramatically rescued the treatment efficacy of meropenem in three infection models. Conclusions and implications: Our observations indicated that dexrazoxane, embelin, candesartan cilexetil and nordihydroguaiaretic acid are promising carbapenem adjuvants against metallo-ss-lactamases-positive carbapenem resistant bacterial pathogens.

Synthesis of 1,3,4-trisubstituted pyrrolidines as meropenem adjuvants targeting New Delhi metallo-β-lactamase

Discovery of Thiosemicarbazone Derivatives As Effective New Delhi Metallo-Β-lactamase-1 (NDM-1) Inhibitors Against NDM-1 Producing Clinical Isolates.

Diaryl-substituted thiosemicarbazone: A potent scaffold for the development of New Delhi metallo-β-lactamase-1 inhibitors

1,2-Isoselenazol-3(2H)-one derivatives as NDM-1 inhibitors displaying synergistic antimicrobial effects with meropenem on NDM-1 producing clinical isolates

Novel Mercapto Propionamide Derivatives with Potent New Delhi Metallo-β-Lactamase-1 Inhibitory Activity and Low Toxicity

Inhibitor discovery of full-length New Delhi metallo-β-lactamase-1 (NDM-1).

N-acylhydrazones confer inhibitory efficacy against New Delhi metallo-β-lactamase-1

PHT427 as an effective New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor restored the susceptibility of meropenem against Enterobacteriaceae producing NDM-1

Discovery of Isatin-Β-methyldithiocarbazate Derivatives As New Delhi Metallo- Β-Lactamase-1 (NDM-1) Inhibitors Against NDM-1 Producing Clinical Isolates

Design, synthesis and antibacterial activity evaluation of ebselen derivatives in NDM-1 producing bacteria

Systematic research of H2dedpa derivatives as potent inhibitors of New Delhi Metallo-β-lactamase-1

Discovery of Adjuvants with Antibacterial Potentiation Activity Against Carbapenemase-Producing Enterobacterales Based on in Silico Virtual Screening.

Quinolinyl sulfonamides and sulphonyl esters exhibit inhibitory efficacy against New Delhi metallo-β-lactamase-1 (NDM-1)

Design of Dipicolinic Acid Derivatives As New Delhi Metallo-Β-lactamase-1 Inhibitors Using a Combined Computational Approach.

Stereochemically altered cephalosporins as potent inhibitors of New Delhi metallo-β-lactamases

Design, synthesis, biological evaluation and in silico studies of certain aryl sulfonyl hydrazones conjugated with 1,3-diaryl pyrazoles as potent metallo-β-lactamase inhibitors

New derivatives of dipicolinic acid as metallo-β-lactamase NDM-1 inhibitors

Novel Metallo‐β‐lactamases Inhibitors Restore the Susceptibility of Carbapenems to New Delhi Metallo‐lactamase‐1 (ndm‐1)‐harbouring Bacteria

((S)-3-mercapto-2-methylpropanamido)acetic Acid Derivatives As Metallo-Β-lactamase Inhibitors: Synthesis, Kinetic and Crystallographic Studies.

Rational design of novel compounds to serve as potential NDM-1 inhibitors using molecular docking, molecular dynamics simulation, and physicochemical studies

A Novel Potent Metal-Binding NDM-1 Inhibitor Was Identified by Fragment Virtual, SPR and NMR Screening.